Insulet to Showcase Its Omnipod DASH™ Insulin Management System at the American Association of Diabetes Educators Annual Conference
BILLERICA, Mass.--(BUSINESS WIRE)-- Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System (Omnipod System), today announced it will showcase its recently FDA cleared Omnipod DASH™ Insulin Management System (Omnipod DASH System), during the American Association of Diabetes Educators meeting at the Baltimore Convention Center in Baltimore, Maryland on August 17-20, 2018.
Insulet will feature its new, innovative Omnipod DASH System in a variety of hands-on, interactive product demonstrations at its exhibit booth (#611). The Company will also host a panel discussion and product theater, the details for which are below.
Technology and Time in Range: The DASH Towards a Solution Panel Discussion:
- Thursday, August 16th, 7 – 9PM
- Harbor Tower, Cook Commons Room, 100 International Drive, Baltimore, MD
- Moderator: Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Medical Director, Insulet
- Panelists: Cari Berget, RN, MPH, CDE, Clinical Research Team Manager, University of Colorado Denver School of Medicine, Department of Pediatrics, Barbara Davis Center for Diabetes; Donna L. Jornsay, MS, BSN, RN, CPNP, CDE, CDTC, BC-ADM, Diabetes Educator and Nurse Consultant; Christel Aprigliano, CEO The Diabetes Collective and Vice President of DPAC; Caroline Hill, Podder, Pre-Med Student at Louisiana Tech University, College Diabetes Network Chapter President, Diabetes Blogger
The Omnipod DASH System: Simplifying Insulin Delivery for Your Patients and Your Practice Product Theater:
- Friday, August 17th, 12:15 – 1PM
- Baltimore Convention Center, Exhibit Hall, Product Theater A
- Presenter: Dr. Trang Ly, MBBS, FRACP, PhD, Senior Vice President and Medical Director, Insulet
“We are excited for the opportunity to introduce Omnipod DASH to the diabetes educators, many of whom provided incredibly helpful input on DASH’s functionality and design at last year’s AADE,” said Bret Christensen, Chief Commercial Officer. “We are committed to delivering innovative products to the diabetes community to reduce the burden of diabetes for both patients and clinicians. We are thrilled to present DASH to the diabetes educator community so they can see firsthand how our innovative product will help make diabetes a smaller part of their patients’ lives.”
About Insulet Corporation:
Insulet Corporation (NASDAQ: PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to making the lives of people with diabetes and other conditions easier through the use of its Omnipod product platform. The Omnipod Insulin Management System provides a unique alternative to traditional insulin delivery methods. With its simple, wearable design, the disposable Pod provides up to three days of non-stop insulin delivery, without the need to see or handle a needle. Insulet also leverages the unique design of its Pod, by tailoring its Omnipod technology platform for the delivery of non-insulin subcutaneous drugs across multiple therapeutic areas. Founded in 2000, more than 140,000 users across the globe rely on Insulet’s Omnipod Insulin Management System to bring simplicity and freedom to their lives. For more information, please visit: www.insulet.com and www.myomnipod.com.
*On July 1, 2018, Insulet assumed direct operations of its Omnipod Insulin Management System product line in Europe, including sales, marketing, training and customer support activities. This allows Insulet to be closer to the diabetes community and identify opportunities to support European customer needs over the long-term, as Insulet does in the United States and Canada.
This press release may contain forward-looking statements concerning Insulet's expectations, anticipations, intentions, beliefs or strategies regarding the future. These forward-looking statements are based on its current expectations and beliefs concerning future developments and their potential effects on Insulet. There can be no assurance that future developments affecting Insulet will be those that it has anticipated. These forward-looking statements involve a number of risks, uncertainties (some of which are beyond its control) or other assumptions that may cause actual results or performance to be materially different from those expressed or implied by these forward-looking statements, and other risks and uncertainties described in its Annual Report on Form 10-K, which was filed with the Securities and Exchange Commission on February 22, 2018 in the section entitled "Risk Factors," and in its other filings from time to time with the Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should any of its assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. Insulet undertakes no obligation to publicly update or revise any forward-looking statements.
© 2018 Insulet Corporation. DASH, Omnipod and the Omnipod logo are trademarks or registered trademarks of Insulet Corporation. All rights reserved.
Investor Relations and Corporate Communications Contact:
Deborah R. Gordon, 978-600-7717
Vice President, Investor Relations and Corporate Communications
Natalie MacMillan, 978-600-7421
Marketing Manager, Global Public Relations & Field Programs
Source: Insulet Corporation